These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 8879230

  • 1. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice.
    Screpanti I, Musiani P, Bellavia D, Cappelletti M, Aiello FB, Maroder M, Frati L, Modesti A, Gulino A, Poli V.
    J Exp Med; 1996 Oct 01; 184(4):1561-6. PubMed ID: 8879230
    [Abstract] [Full Text] [Related]

  • 2. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice.
    Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, Lazzaro D, Sellitto C, Scarpa S, Bellavia D, Lattanzio G.
    EMBO J; 1995 May 01; 14(9):1932-41. PubMed ID: 7744000
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-6 and CAAT/enhancer binding protein beta-deficient mice act as tools to dissect the IL-6 signalling pathway and IL-6 regulation.
    Alonzi T, Gorgoni B, Screpanti I, Gulino A, Poli V.
    Immunobiology; 1997 Dec 01; 198(1-3):144-56. PubMed ID: 9442386
    [Abstract] [Full Text] [Related]

  • 4. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
    Nishi J, Maruyama I.
    Leuk Lymphoma; 2000 Jul 01; 38(3-4):387-94. PubMed ID: 10830746
    [Abstract] [Full Text] [Related]

  • 5. Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman's disease.
    Kinney MC, Hummell DS, Villiger PM, Hourigan A, Rollins-Smith L, Glick AD, Lawton AR.
    J Clin Immunol; 1994 Nov 01; 14(6):382-90. PubMed ID: 7883866
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-6 gene expression in Castleman's disease.
    Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, Galanaud P, Diebold J, Emilie D.
    Blood; 1991 Dec 01; 78(11):2923-30. PubMed ID: 1954381
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A case of multicentric Castleman's disease demonstrating severe eosinophilia and enhanced production of interleukin-5.
    Ishii T, Tatekawa T, Koseto M, Ishii M, Kobayashi H, Koike M, Fujii T, Saeki Y.
    Eur J Haematol; 2003 Feb 01; 70(2):115-8. PubMed ID: 12581193
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Castleman's disease associated with myasthenia gravis.
    Day JR, Bew D, Ali M, Dina R, Smith PL.
    Ann Thorac Surg; 2003 May 01; 75(5):1648-50. PubMed ID: 12735602
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-6-producing giant cell carcinoma of the lung with multicentric Castleman's disease-like presentation.
    Higashikuni Y, Mori M, Kino H.
    Intern Med; 2007 May 01; 46(10):669-73. PubMed ID: 17527041
    [Abstract] [Full Text] [Related]

  • 12. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease.
    Parravicini C, Corbellino M, Paulli M, Magrini U, Lazzarino M, Moore PS, Chang Y.
    Am J Pathol; 1997 Dec 01; 151(6):1517-22. PubMed ID: 9403701
    [Abstract] [Full Text] [Related]

  • 13. A benign course of multicentric Castleman's disease with involvement of the spleen and bone marrow.
    Levo Y, Behar AJ, Blum I, Frish B.
    Eur J Haematol; 1987 Nov 01; 39(5):471-4. PubMed ID: 3691764
    [Abstract] [Full Text] [Related]

  • 14. Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type.
    Ohyashiki JH, Ohyashiki K, Kawakubo K, Serizawa H, Abe K, Mikata A, Toyama K.
    Am J Clin Pathol; 1994 Mar 01; 101(3):290-5. PubMed ID: 8135184
    [Abstract] [Full Text] [Related]

  • 15. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
    Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K.
    Blood; 2000 Jan 01; 95(1):56-61. PubMed ID: 10607684
    [Abstract] [Full Text] [Related]

  • 16. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
    Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, Corringham RE, Kurzrock R.
    Mol Cancer Ther; 2007 Sep 01; 6(9):2386-90. PubMed ID: 17766835
    [Abstract] [Full Text] [Related]

  • 17. Idiopathic multicentric Castleman's disease: a clinicopathologic study in comparison with IgG4-related disease.
    Otani K, Inoue D, Fujikura K, Komori T, Abe-Suzuki S, Tajiri T, Itoh T, Zen Y.
    Oncotarget; 2018 Jan 23; 9(6):6691-6706. PubMed ID: 29467920
    [Abstract] [Full Text] [Related]

  • 18. Castleman's disease: a study of a rare lymphoproliferative disorder in a university hospital.
    Al-Amri AM, Abdul-Rahman IS, Ghallab KQ.
    Gulf J Oncolog; 2010 Jan 23; (7):25-36. PubMed ID: 20164006
    [Abstract] [Full Text] [Related]

  • 19. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.
    Nishi J, Arimura K, Utsunomiya A, Yonezawa S, Kawakami K, Maeno N, Ijichi O, Ikarimoto N, Nakata M, Kitajima I, Fukushige T, Takamatsu H, Miyata K, Maruyama I.
    Br J Haematol; 1999 Mar 23; 104(3):482-5. PubMed ID: 10086783
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.